QED Therapeutics, an affiliate company of BridgeBio Pharma, is dedicated to developing meaningful treatment options for those with achondroplasia and pursuing research to address the needs of the community. We are studying whether an investigational agent (infigratinib) has the potential to address the root cause of irregular bone growth in achondroplasia, by decreasing the overactivity of the FGFR3 receptor.
| Website | https://qedtx.com/ |
| Employees | 13 (4 on RocketReach) |
| Founded | 2018 |
| Address | 421 Kipling St., Palo Alto, California 94301, US |
| Phone | +1 877-280-5655 |
| Technologies |
JavaScript
,
HTML
,
PHP
+27 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Science and Engineering, Health Care, Therapeutics |
| Keywords | Patient Care, Treatment Options, Rare Disease Therapeutics, Drug Development, Pharmaceutical Research, Clinical Trials, Biotechnology, Genetic Disorders, Pediatric Therapeutics, Medical Research, Innovative Therapies, New Treatments, Disease Research, Pharmaceutical, Therapeutics, Research And Development, Health, Medicine |
| Competitors | Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Amgen, Regeneron, Incyte, Exelixis, Celerion, Lengo Therapeutics +38 more (view full list) |
Looking for a particular QED Therapeutics employee's phone or email?
QED Therapeutics Questions
Quoc M is the Senior Director, Head of Statistical Programming of QED Therapeutics.
4 people are employed at QED Therapeutics.
QED Therapeutics is based in Palo Alto, California.
Top QED Therapeutics Employees
-
Quoc M
Senior Director, Head of Statistical Programming at QED Therapeutics
California, United States24 -
Anne Gilbert
Director of Patient Advocacy at QED Therapeutics
San Francisco, California, United States11 -
Ray Villar
CMC Technical Writer at QED Therapeutics
Daly City, CA, US2 -
Micaela Rodine
Associate Director, Clinical Operations at QED Therapeutics
California, United States14
Related Companies
